AN2 Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
ANTX$4.000.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 16. Form 10-K Summary
None.
Exhibit Index
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
| 3.1 | Amended and Restated Certificate of Incorporation. | 8-K | 001-41331 | 3.1 | June 24 2025 |
| 3.2 | Amended and Restated Bylaws. | S-1 | 333-263295 | 3.4 | March 4, 2022 |
| 3.3 | Certificate of Designations of Series A Junior Participating Preferred Stock of AN2 Therapeutics, Inc. filed with the Secretary of State of the State of Delaware on August 15, 2024. | 8-K | 001-41331 | 3.1 | August 19, 2024 |
| 4.1 | Form of Common Stock Certificate. | S-1 | 333-263295 | 4.1 | March 21, 2022 |
| 4.2 | Amended and Restated Investors’ Rights Agreement, by and among the Registrant and certain of its stockholders, dated March 5, 2021. | S-1 | 333-263295 | 4.2 | March 4, 2022 |
| 4.3* | Description of Securities. | ||||
| 4.4 | Form of Pre-Funded Warrant. | 8-K | 001-41331 | 4.1 | June 20, 2025 |
| 4.5 | Form of 2026 Pre-Funded Warrant. | 8-K | 001-41331 | 4.1 | March 10, 2026 |
| 10.1# | AN2 Therapeutics, Inc. 2017 Equity Incentive Plan, as amended. | S-1 | 333-263295 | 10.1 | March 4, 2022 |
| 10.2# | Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise and Early Exercise Stock Purchase Agreement under the AN2 Therapeutics, Inc. 2017 Equity Incentive Plan. | S-1 | 333-263295 | 10.2 | March 4, 2022 |
| 10.3# | AN2 Therapeutics, Inc. 2022 Equity Incentive Plan | 10-K | 001-41331 | 10.3 | March 29, 2024 |
| 10.4# | Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan. | S-1 | 333-263295 | 10.4 | March 4, 2022 |
| 10.5# | Form of Restricted Stock Unit Grant Notice and Award Agreement under the AN2 Therapeutics, Inc. 2022 Equity Incentive Plan. | 10-K | 001-41331 | 10.5 | March 29, 2024 |
| 10.6# | AN2 Therapeutics, Inc 2022 Employee Stock Purchase Plan. | 10-K | 001-41331 | 10.6 | March 29, 2024 |
| 10.7# | AN2 Therapeutics, Inc. Amended and Restated 2022 Non-Employee Director Compensation Policy. | 10-Q | 001-41331 | 10.1 | August 12, 2025 |
| 10.8# | AN2 Therapeutics, Inc. Officer Severance Plan. | S-1 | 333-263295 | 10.8 | March 4, 2022 |
| 10.9# | Form of Indemnity Agreement by and between the Registrant and its directors and executive officers. | S-1 | 333-263295 | 10.9 | March 4, 2022 |
| 10.10# | Offer Letter by and between the Registrant and Eric Easom, dated November 19, 2019. | S-1 | 333-263295 | 10.10 | March 4, 2022 |
| 10.11#* | Amended and Restated Offer Letter by and between the Registrant and Lucy Day, dated January 29, 2026. | ||||
| 10.12‡ | License Agreement by and between the Registrant and Anacor Pharmaceuticals, Inc., dated November 20, 2019, as amended on December 3, 2021. | S-1 | 333-263295 | 10.13 | March 4, 2022 |
| 10.13‡ | License Agreement by and between the Registrant and Brii Biosciences Limited, dated November 20, 2019. | S-1 | 333-263295 | 10.14 | March 4, 2022 |
| 10.14 | Amended and Restated Global Health Agreement by and among the Registrant, Adjuvant Global Health Technology Fund L.P., and Adjuvant Global Health Technology Fund DE L.P., dated March 5, 2021. | S-1 | 333-263295 | 10.15 | March 4, 2022 |
| Incorporated by Reference | |||||
|---|---|---|---|---|---|
| ExhibitNumber | Description | Form | File No. | Exhibit | Filing Date |
| 10.15# | Offer Letter by and between the Registrant and Joshua Eizen, dated September 19, 2022. | 10-Q | 001-41331 | 10.1 | November 9, 2022 |
| 10.16‡ | Exclusive Patent License Agreement, dated October 10, 2023, by and between the Registrant and the University of Georgia Research Foundation, Inc | 10-K | 001-41331 | 10.18 | March 25, 2025 |
| 10.17 | Securities Purchase Agreement, dated March 8, 2026, by and among AN2 Therapeutics, Inc. and the Purchasers. | 8-K | 001-41331 | 10.1 | March 10, 2026 |
| 10.18 | Registration Rights Agreement, dated March 10, 2025, by and among AN2 Therapeutics, Inc. and the investors party thereto. | 8-K | 001-41331 | 10.2 | March 10, 2026 |
| 19.1 | AN2 Therapeutics, Inc. 2022 Insider Trading Policy | 10-K | 001-41331 | 19.1 | March 25, 2025 |
| 23.1* | Consent of PricewaterhouseCoopers LLP, independent registered public accounting firm. | ||||
| 24.1* | Power of Attorney (incorporated by reference to the signature page to this Annual Report on Form 10-K.) | ||||
| 31.1* | Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 31.2* | Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.1*† | Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 32.2*† | Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | ||||
| 97.1 | Compensation Recovery Policy. | 10-K | 001-41331 | 97.1 | March 29, 2024 |
| 101.INS | Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document. | ||||
| 101.SCH | Inline XBRL Taxonomy Extension Schema With Embedded Linkbase Documents** | ||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
- Filed herewith.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.